Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the ABCA1 transporter

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 77-82

  Boone, Lindsey R ^a   Lagor, William R ^b   de la Llera Moya, Margarita ^c   Niesen, Melissa I ^a   Rothblat, George H ^c   Ness, Gene C ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

ABCA1 transporter; Atherosclerosis; Cholesterol transport; Thyroid hormone

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G5; ABC TRANSPORTER G8; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; CHOLESTEROL; FETUIN A; HIGH DENSITY LIPOPROTEIN; LIOTHYRONINE; THYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GEL FILTRATION CHROMATOGRAPHY; MACROPHAGE; MALE; MICROARRAY ANALYSIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLESTEROL, HDL; CRICETINAE; LIPIDS; LIVER; MACROPHAGES; MALE; MICE; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARTICLE SIZE; RATS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID HORMONES;

EID: 80052259834     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.028     Document Type: Article

References (33)

1. Ness G.C. Thyroid hormone. Basis for its hypocholesterolemic effect. JFMA 1991, 78:383-385.
2. Martinez-Triguero M.L., Hernandez-Mijares A., Nguyen T.T., et al. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998, 73:837-841.
3. Galman C., Bonde Y., Matasconi M., Angelin B., Rudling M. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 2008, 134:1127-1136.
4. Ness G.C., Zhao Z. Thyroid hormone rapidly induces hepatic LDL receptor mRNA levels in hypophysectomized rats. Arch Biochem Biophys 1994, 315:199-202.
5. Erion M.D., Cable E.E., Ito B.R., et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007, 104:15490-15495.
6. Tancevski I., Wehinger A., Demetz E., et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res 2009, 50:938-944.
7. Berkenstam A., Kristensen J., Mellstrom K., et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008, 105:663-667.
8. Tancevski I., Demetz E., Eller P., et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One 2010, 5:e8722.
9. Lagor W.R., Millar J.S. Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease. J Recept Ligand Channel Res 2010, 1-14.
10. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999, 100:594-598.
11. Duong P.T., Weibel G.L., Lund-Katz S., Rothblat G.H., Phillips M.C. Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008, 49:1006-1014.
12. Out R., Hoekstra M., Habets K., et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008, 28:258-264.
13. Adorni M.P., Zimetti F., Billheimer J.T., et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48:2453-2462.
14. Ness G.C., Lopez D., Chambers C.M., et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 1998, 56:121-129.
15. Wilensky R.L., Shi Y., Mohler E.R., et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008, 14:1059-1066.
16. Sankaranarayanan S., Oram J.F., Asztalos B.F., et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 2009, 50:275-284.
17. Favari E., Calabresi L., Adorni M.P., et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 2009, 48:11067-11074.
18. Santi A., Duarte M.M., Moresco R.N., et al. Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clin Chem Lab Med 2010, 48:1635-1639.
19. Kvetny J., Heldgaard P.E., Bladbjerg E.M., Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004, 61:232-238.
20. Ji Y., Wang N., Ramakrishnan R., et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999, 274:33398-33402.
21. Ji Y., Jian B., Wang N., et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997, 272:20982-20985.
22. de la Llera Moya M., Drazul-Schrader D., Asztalos B.F., et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010, 30:796-801.
23. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010, 21:229-238.
24. Van Lenten B.J., Wagner A.C., Anantharamaiah G.M., et al. Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 2009, 11:52-57.
25. Sacks F.M., Rudel L.L., Conner A., et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009, 50:894-907.
26. Khera A.V., Cuchel M., de la Llera Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
27. Bilgir O., Kebapcilar L., Bilgir F., et al. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 2010, 49:1281-1285.
28. Weikert C., Stefan N., Schulze M.B., et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008, 118:2555-2562.
29. Westenfeld R., Schafer C., Kruger T., et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol 2009, 20:1264-1274.
30. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119:1135-1145.
31. Ivandic B., Castellani L.W., Wang X.P., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999, 19:1284-1290.
32. Divchev D., Schieffer B. The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?. Vasc Health Risk Manag 2008, 4:597-604.
33. Menschikowski M., Lattke P., Bergmann S., Jaross W. Exposure of macrophages to PLA2-modified lipoproteins leads to cellular lipid accumulations. Anal Cell Pathol 1995, 9:113-121.